- Home
- PGC vs ACRS Comparison
PGC vs ACRS Comparison
Compare PGC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGC | ACRS |
|---|---|---|
| Founded | 1921 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.7M | 868.5M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PGC | ACRS |
|---|---|---|
| Price | $44.32 | $6.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $40.50 | $10.20 |
| AVG Volume (30 Days) | 127.0K | ★ 1.9M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | 13.51 | ★ 69.01 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $282,995,000.00 | $1,683,000.00 |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | $4.24 |
| P/E Ratio | $27.02 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.71 | $1.74 |
| 52 Week High | $49.14 | $6.60 |
Technical Indicators
Market Signals| Indicator | PGC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 51.71 |
| Support Level | $43.44 | $5.64 |
| Resistance Level | $47.47 | $6.56 |
| Average True Range (ATR) | 0.92 | 0.30 |
| MACD | -0.14 | -0.05 |
| Stochastic Oscillator | 4.35 | 39.59 |
Price Performance
Historical ComparisonAbout PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.